Preeclampsia Risk Evaluation for 2nd and 3rd Trimester Build info

Synonyms

• PREECLAMPSIA 2ND 3RD TRIMESTER
• PRECLAMPSIA 2nd 3rd TRI
• LAB14016

Short Name

PREECLAMPSIA 2ND 3RD TRIMESTER

Procedure Master Number

LAB14016

Procedure ID

182897

Clinical Info

The 2nd 3rd Trimester Preeclampsia test is a mid to late trimester prognostic test used to aid in the risk assessment of pregnant women (singleton pregnancies between gestational age 23+0 to 34+6/7 weeks) hospitalized for hypertensive disorders of pregnancy (preeclampsia, chronic hypertension with or without superimposed preeclampsia, or gestational hypertension) for progression to preeclampsia with severe features (as defined by the American College of Obstetricians and Gynecologists (ACOG) guidelines1) within 2 weeks of presentation. 
The test incorporates the maternal serum markers soluble fms-like tyrosine kinase-1 (sFlt-1) and Placental Growth Factor (PlGF).  The ratio of the anti-angiogenic sFlt-1 to the angiogenic PlGF help to inform clinicians which patient would be at higher risk for developing the ACOG classification of PE with severe features. Thereafter, women whose test was positive (i.e. high risk) would receive stepped-up care. The elevation in the sFlt-1/PlGF ratio occurs prior to ACOG defined thresholds for delivery (e.g., LFT elevations, thrombocytopenia abnormal umbilical Doppler), and therefore is useful to step-up appropriate care and intensify surveillance before severe features develop.

Specimen Type

Blood

Container

Gold Top Serum Separator Tube

Collection Instructions

The specimen draw is from 23w0d to 34w6d gestation.
Collect blood by venipuncture, allow it to clot and separate the serum by centrifugation.
Specimen Volume: 3 ml serum (0.5 ml Min)
Specimen Rejection Criteria:
    Incorrect tube type
    Insufficient volume 
    Gross hemolysis/lipemia
    Out of gestational age range
Patients should avoid intravenous heparin within 24 hours prior to venipuncture.Test should not be performed in women receiving exogenous PlGF-2 or PlGF-3 for therapeutic use at concentration higher than 100 pg/mL.Test should not be performed in multiple pregnancy.

Transport Instructions

Refrigerate prior to shipping for overnight delivery.
Transport temperature: Ambient

Specimen Stability

6 Days Room Temperature
14 Days Refrigerated

Methodology

Time-Resolved Amplified Cryptate Emission (TRACE). This test is a modification of an FDA approved method.  The performance characteristics were validated/verified by Northwell Health Laboratories. The methods and performance characteristics have been reviewed and approved by the New York State Department of Health.

Days Performed

Monday through Friday.   TAT 1 business day upon receipt

Performing Laboratory

Northwell Core Lab at CFAM

CPT

83520 x 2

PDM

245507

Results